DCT

1:25-cv-00311

Sumitomo Pharma Switzerland GmbH v. Apotex Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

Case Timeline

Date Event
2012-09-28 Earliest Priority Date ('178, '714, '198, '809, '990, '12,325,714, '12,097,198, '12,144,809, '12,336,990 Patents)
2015-02-26 Earliest Priority Date ('170 Patent)
2016-09-30 Earliest Priority Date ('198, '809, '990 Patents)
2019-07-16 U.S. Patent No. 10,350,170 Issued
2020-12-18 FDA Approval of Orgovyx® New Drug Application
2023-10-24 U.S. Patent No. 11,795,178 Issued
2024-09-24 U.S. Patent No. 12,097,198 Issued
2024-11-19 U.S. Patent No. 12,144,809 Issued
2025-06-10 U.S. Patent No. 12,325,714 Issued
2025-06-11 '714 Patent Listed in Orange Book
2025-06-20 Sandoz Sends Paragraph IV Notice Letter
2025-06-24 U.S. Patent No. 12,336,990 Issued
2025-06-25 '990 Patent Listed in Orange Book
2025-07-29 Plaintiffs Provide Sandoz Copies of '714 and '990 Patents
2025-08-01 Original Complaint Filed
2026-02-27 Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,795,178 - Compositions of Thienopyrimidine Derivatives

  • Patent Identification: U.S. Patent No. 11,795,178, "Compositions of Thienopyrimidine Derivatives," issued October 24, 2023 Compl. ¶19

The Invention Explained

  • Problem Addressed: The patent background notes a demand for a safe and high-yield production method for certain thienopyrimidine derivatives that have a GnRH antagonistic action '178 Patent, col. 2:8-16
  • The Patented Solution: The patent claims a specific method of producing the active pharmaceutical ingredient, relugolix. The claimed solution involves reacting three specific components: a 6-(4-aminophenyl)-dione precursor, 1,1'-carbonyldiimidazole, and methoxyamine to form the final compound '178 Patent, claim 1 '178 Patent, col. 12:47-66 This method is presented as a way to obtain the desired compound with high quality and yield '178 Patent, abstract
  • Technical Importance: The invention purports to provide a safer and more efficient synthesis process for a clinically important GnRH antagonist, which is significant for manufacturing pharmaceutical-grade active ingredients '178 Patent, col. 2:23-26

Key Claims at a Glance

  • The complaint asserts infringement of at least independent claim 1 Compl. ¶40
  • The essential elements of independent claim 1 are:
    • A method of producing 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea or a salt thereof,
    • which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or a salt thereof,
    • 1,1'-carbonyldiimidazole or a salt thereof, and
    • methoxyamine or a salt thereof '178 Patent, claim 1
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 12,325,714 - Compositions of Thienopyrimidine Derivatives

  • Patent Identification: U.S. Patent No. 12,325,714, "Compositions of Thienopyrimidine Derivatives," issued June 10, 2025 Compl. ¶20

The Invention Explained

  • Problem Addressed: Similar to the '178 Patent, this patent addresses the need for a production method that yields the thienopyrimidine derivative with high quality and purity '714 Patent, col. 2:8-16
  • The Patented Solution: The patent claims solid mixtures that contain the active ingredient relugolix along with specific, named chemical impurities. Asserted claims 1, 11, and 19 each claim a mixture of relugolix with a different impurity, such as 1-{4-[1-(2,6-difluorobenzyl)-...-3-(6-oxo-1,6-dihydropyridazin-3-yl)-...]phenyl}-3-methoxyurea '714 Patent, claims 1, 11, 19 The invention is thus a composition defined by the presence of the active drug and certain process-related impurities.
  • Technical Importance: By claiming a composition with specific impurities, the patent may seek to cover drug products produced by certain manufacturing processes that inherently generate these impurities, thereby creating a potential barrier to entry for generics made by similar methods '714 Patent, abstract

Key Claims at a Glance

  • The complaint asserts infringement of at least independent claims 1, 11, and 19 Compl. ¶50

  • The essential elements of independent claim 1 are:

    • A solid mixture comprising 1-{4-[1-(2,6-difluorobenzyl)-...]-3-methoxyurea, or a salt or solvate thereof, and
    • 1-{4-[1-(2,6-difluorobenzyl)-...-3-(6-oxo-1,6-dihydropyridazin-3-yl)-...]phenyl}-3-methoxyurea '714 Patent, claim 1

  • The essential elements of independent claim 11 are:

    • A solid mixture comprising 1-{4-[1-(2,6-difluorobenzyl)-...]-3-methoxyurea, or a salt or solvate thereof, and
    • N-{4-[1-(2,6-difluorobenzyl)-...]-N,N'-dimethoxydicarbonimidic diamide '714 Patent, claim 11

  • The essential elements of independent claim 19 are:

    • A solid mixture comprising 1-{4-[1-(2,6-difluorobenzyl)-...]-3-methoxyurea, or a salt or solvate thereof, and
    • 1-(2,6-Difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxy-pyridazin-3-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione '714 Patent, claim 19

  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

  • Multi-Patent Capsule: U.S. Patent No. 12,097,198

    • Patent Identification: U.S. Patent No. 12,097,198, "Treatment of Prostate Cancer," issued September 24, 2024 Compl. ¶21
    • Technology Synopsis: The patent claims methods for treating prostate cancer by administering the active ingredient relugolix. The claims cover specific oral dosage regimens for the drug '198 Patent, abstract '198 Patent, claim 1
    • Asserted Claims: Claims 1-2, 4-6, and 10-12 Compl. ¶61 Independent claim 1 is a method of treating prostate cancer comprising administering once-daily at least 80 mg of relugolix '198 Patent, claim 1
    • Accused Features: The accused feature is the intended and instructed use of Sandoz's ANDA product for the treatment of prostate cancer, which Plaintiffs allege will be directed by Sandoz's proposed product labeling Compl. ¶¶63-65

  • Multi-Patent Capsule: U.S. Patent No. 12,144,809

    • Patent Identification: U.S. Patent No. 12,144,809, "Treatment of Prostate Cancer," issued November 19, 2024 Compl. ¶22
    • Technology Synopsis: The patent claims a method of treating prostate cancer with relugolix in patients who also require co-administration of a P-glycoprotein (P-gp) inhibitor. The method specifies that the doses of relugolix and the P-gp inhibitor must be separated by at least six hours to manage potential drug interactions that can increase relugolix exposure '809 Patent, abstract '809 Patent, claim 1 Compl. ¶¶71-74
    • Asserted Claims: Claims 1, 3, 5, 9, 12, 19, and 23-29 Compl. ¶80 Independent claim 1 covers the method of dose separation '809 Patent, claim 1
    • Accused Features: The infringement allegation centers on Sandoz's proposed product label, which Plaintiffs allege will instruct doctors and patients to practice the claimed dosing regimen when co-administering the ANDA product with a P-gp inhibitor Compl. ¶¶76-78

  • Multi-Patent Capsule: U.S. Patent No. 12,336,990

    • Patent Identification: U.S. Patent No. 12,336,990, "Treatment of Prostate Cancer," issued June 24, 2025 Compl. ¶23
    • Technology Synopsis: The patent claims methods of treating prostate cancer by administering relugolix, including specific oral dosage regimens involving load and maintenance doses '990 Patent, abstract
    • Asserted Claims: Claims 1-2, 4-7, and 15-30 Compl. ¶90 Independent claim 1 is a method of treating prostate cancer comprising administering a specific loading dose followed by a maintenance dose of relugolix '990 Patent, claim 1
    • Accused Features: The accused feature is the intended and instructed use of Sandoz's ANDA product according to the claimed dosing schedules, as allegedly directed by the proposed product labeling Compl. ¶¶93-94

  • Multi-Patent Capsule: U.S. Patent No. 10,350,170

    • Patent Identification: U.S. Patent No. 10,350,170, "Solid Preparation," issued July 16, 2019 Compl. ¶24
    • Technology Synopsis: The patent addresses the problem of chemical instability of the relugolix compound when formulated into a solid tablet. The invention claims to solve this by providing a specific solid preparation (tablet) that includes not less than 25% by mass of the active compound and D-mannitol particles of a specific size, which is purported to improve the compound's stability '170 Patent, col. 1:49-57 '170 Patent, col. 2:2-6
    • Asserted Claims: At least claim 5 Compl. ¶101
    • Accused Features: The accused feature is Sandoz's 120 mg solid tablet formulation itself, which Plaintiffs allege contains the elements of the claimed solid preparation, either literally or under the doctrine of equivalents Compl. ¶104

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendant Sandoz's Abbreviated New Drug Application No. 219913 product, which is a generic version of Orgovyx® (relugolix) in 120 mg tablets (the "ANDA Product") Compl. ¶1

Functionality and Market Context

  • The ANDA Product contains the active ingredient relugolix, a nonpeptide GnRH receptor antagonist for oral administration Compl. ¶17
  • Sandoz has represented to the FDA that its ANDA Product has the same active ingredient, dosage form, and strength as Orgovyx®, and is bioequivalent to Orgovyx® Compl. ¶28
  • The complaint alleges that Sandoz's proposed labeling for its ANDA product will instruct healthcare providers and patients on methods of use, including a specific dosing regimen for co-administration with P-gp inhibitors, that allegedly practice methods claimed in the patents-in-suit (Compl. ¶76; Compl. ¶77; Compl. ¶78).

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim-chart analysis of the infringement allegations for the '178 Patent or the '714 Patent. The infringement theory for the '178 Patent is that Sandoz's ANDA Product, or its active ingredient, is or will be manufactured using the process claimed in at least claim 1 of the '178 patent Compl. ¶40 Compl. ¶41 For the '714 Patent, the infringement theory is that Sandoz's ANDA product is a solid mixture that contains the active ingredient and the specific impurities recited in at least claims 1, 11, and 19 Compl. ¶50 Compl. ¶51

  • Identified Points of Contention:
    • '178 Patent (Process): A primary question for the court will be evidentiary and factual: Does Sandoz, or its active ingredient supplier, utilize a manufacturing process that performs the specific sequence of reacting the three components required by claim 1? The resolution of this question will depend on discovery of Sandoz's confidential ANDA filing and manufacturing records.
    • '714 Patent (Composition): The infringement analysis may raise two key questions. First, an analytical question: Does Sandoz's ANDA Product contain the specific chemical impurities recited in claims 1, 11, and 19? Second, a question of claim scope: Does the term "solid mixture" as used in the claims encompass a final formulated drug product containing excipients, or is its scope limited to a pre-formulation blend of the active ingredient and its impurities?

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "solid mixture" (from '714 Patent, claims 1, 11, 19)
  • Context and Importance: The definition of "solid mixture" is critical because Sandoz's product is a finished tablet containing numerous excipients, not just the active ingredient and an impurity. Practitioners may focus on this term because Sandoz could argue that the claims are directed to a pre-formulation blend of active pharmaceutical ingredient (API) and impurities, not the final drug product that also contains binders, fillers, and other excipients.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain and ordinary meaning of "solid mixture" could be interpreted broadly to include any solid-form product containing the specified components, including a finished tablet. The claims use the open-ended transitional phrase "comprising" '714 Patent, claims 1, 11, 19
    • Evidence for a Narrower Interpretation: Other patents in the same family, such as the '170 Patent, use the term "solid preparation" and "tablet" to describe the final dosage form '170 Patent, title '170 Patent, claim 1 The use of the distinct term "solid mixture" in the '714 patent may suggest the patentee intended a different, narrower scope, potentially limited to the API blend before the addition of formulation excipients.
  • The Term: "comprises reacting" (from '178 Patent, claim 1)
  • Context and Importance: This term is central to defining the scope of the claimed manufacturing process. Practitioners may focus on this term because its construction will determine whether the claim covers only single-pot reactions where all components are added together, or also extends to sequential processes where the components are introduced at different stages.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term "comprises" is well-established as open-ended, suggesting the claim is not limited to the recited steps. The specification may describe embodiments where the reactants are added sequentially, which would support a construction covering more than just a one-pot reaction '178 Patent, col. 12:47-66
    • Evidence for a Narrower Interpretation: A defendant may argue that the claim structure-listing the three components following the word "reacting"-implies that the inventive step requires the simultaneous presence and reaction of all three components. Specific examples in the patent might exclusively show all three components being combined in a single step, potentially limiting the claim's scope to that embodiment.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for all six patents-in-suit Compl. ¶41 Compl. ¶51 Compl. ¶62 Compl. ¶81 Compl. ¶91 Compl. ¶102 For the method-of-use patents ('198, '809, '990), the inducement allegations are based on the assertion that Sandoz's proposed product labeling will instruct and encourage healthcare providers and patients to administer the ANDA Product in a manner that practices the claimed methods Compl. ¶64 Compl. ¶78 Compl. ¶94
  • Willful Infringement: The complaint alleges that Sandoz acted "without a reasonable basis for believing that it would not be liable" and that this is an "exceptional case" entitling Plaintiffs to attorneys' fees Compl. ¶47 Compl. ¶58 Compl. ¶68 Compl. ¶87 Compl. ¶98 Compl. ¶109 The basis for knowledge includes Sandoz's Paragraph IV certification regarding the patents Compl. ¶29, the listing of the patents in the FDA's Orange Book Compl. ¶34 Compl. ¶35 Compl. ¶52 Compl. ¶92, and direct correspondence from Plaintiffs providing copies of certain patents Compl. ¶33 Compl. ¶52 Compl. ¶92

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of process verification: For the '178 Patent, can Plaintiffs obtain evidence through discovery to prove that Sandoz's confidential manufacturing process for its relugolix API practices every step of the claimed synthesis method?
  • A key question will be one of analytical detection and claim scope: For the '714 Patent, does Sandoz's final tablet product contain the specific impurities claimed, and can the term "solid mixture" be construed to read on a fully formulated tablet, or is its meaning confined to a pre-formulation active ingredient blend?
  • A third core issue will be one of induced infringement: For the multiple method-of-treatment patents ('198, '809, '990), does the language in Sandoz's proposed product label provide specific instructions that would lead a substantial number of medical professionals to perform the patented methods of administration, including the dose-separation regimen for co-administration with P-gp inhibitors?